A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelmastobart (Primary)
Indications Adrenocortical carcinoma; Advanced breast cancer; Anal cancer; Cholangiocarcinoma; Colon cancer; Head and neck cancer; Malignant melanoma; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Skin cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms STCUBE-001
Sponsors STCube Pharmaceuticals

12 Mar 2024 Status changed from active, no longer recruiting to completed.
20 Nov 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jan 2024.
20 Nov 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com